Sionna Therapeutics (NASDAQ:SION) Cut to Market Perform at Raymond James Financial

Raymond James Financial lowered shares of Sionna Therapeutics (NASDAQ:SION) from a strong-buy rating to a market perform rating in a report published on Monday morning, Marketbeat.com reports.

Other research analysts have also recently issued reports about the company. Stifel Nicolaus reaffirmed a “hold” rating and issued a $7.00 target price on shares of Sionna Therapeutics in a research report on Monday. Wedbush lowered shares of Sionna Therapeutics from an “outperform” rating to a “neutral” rating and set a $5.00 price target on the stock. in a report on Monday. Freedom Capital cut shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 20th. Citizens Jmp reaffirmed a “market outperform” rating and set a $63.00 price objective on shares of Sionna Therapeutics in a report on Tuesday, May 26th. Finally, Wall Street Zen lowered shares of Sionna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. One equities research analyst has rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Sionna Therapeutics currently has an average rating of “Hold” and an average price target of $42.22.

Sionna Therapeutics Trading Up 22.5%

Shares of SION stock opened at $6.25 on Monday. The stock has a 50 day moving average of $40.38 and a two-hundred day moving average of $39.67. Sionna Therapeutics has a 12 month low of $4.01 and a 12 month high of $54.97. The company has a market capitalization of $282.56 million, a P/E ratio of -2.87 and a beta of 1.33.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.02). Sell-side analysts predict that Sionna Therapeutics will post -2.65 earnings per share for the current fiscal year.

Insider Activity at Sionna Therapeutics

In related news, Director Peter A. Thompson sold 115,844 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total transaction of $5,270,902.00. Following the completion of the transaction, the director owned 2,555,877 shares in the company, valued at $116,292,403.50. This trade represents a 4.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 115,844 shares of the business’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $45.50, for a total value of $5,270,902.00. Following the completion of the sale, the director directly owned 2,555,877 shares in the company, valued at approximately $116,292,403.50. This represents a 4.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 403,726 shares of company stock valued at $18,259,354 in the last 90 days. 5.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Sionna Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. UBS Group AG grew its holdings in shares of Sionna Therapeutics by 91.1% in the 4th quarter. UBS Group AG now owns 89,177 shares of the company’s stock worth $3,669,000 after purchasing an additional 42,511 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Sionna Therapeutics by 3.7% during the 4th quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock valued at $48,749,000 after purchasing an additional 41,797 shares during the last quarter. Jennison Associates LLC lifted its holdings in Sionna Therapeutics by 11.8% during the 4th quarter. Jennison Associates LLC now owns 1,115,278 shares of the company’s stock valued at $45,883,000 after purchasing an additional 117,903 shares during the last quarter. Candriam S.C.A. acquired a new position in Sionna Therapeutics in the first quarter valued at about $9,494,000. Finally, Eventide Asset Management LLC acquired a new position in Sionna Therapeutics in the fourth quarter valued at about $26,290,000.

Key Headlines Impacting Sionna Therapeutics

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: The stock’s rebound may reflect bargain hunting and short-term volatility following the steep selloff, although no new positive clinical data were reported.
• Neutral Sentiment: Analyst opinion has broadly converged around a more cautious stance. Royal Bank of Canada upgraded SION to “Sector Perform,” while Stifel Nicolaus assigned a “Hold” rating. Royal Bank of Canada upgrade
• Negative Sentiment: Sionna reported that its Phase 2a PreciSION CF trial of lead candidate SION-719 failed to achieve its key endpoint for sweat-chloride reduction. The drug will not advance as an add-on therapy, severely damaging the company’s near-term cystic-fibrosis development prospects. Sionna halts lead cystic fibrosis drug
• Negative Sentiment: The clinical failure erased roughly 90% of SION’s market value and removed a potential competitive threat to Vertex Pharmaceuticals, whose shares benefited from the news. Vertex rises as Sionna trial fails
• Negative Sentiment: Several firms reduced their ratings, including Lifesci Capital and JonesTrading to “Hold,” Wedbush to “Neutral,” Raymond James to “Market Perform,” and BTIG and Guggenheim to lower ratings. These actions signal reduced confidence after the trial result. Wedbush downgrade
• Negative Sentiment: Levi & Korsinsky announced a pending investor investigation into potential securities-law violations related to disclosures that allegedly indicated SION-719 was on track before the failed trial outcome. The investigation adds legal and reputational risk. Sionna investor investigation notice

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.